NCT06075563 Total Lymphoid Irradiation as Conditioning for Pediatric Haploidentical Hematopoietic Stem Cell Transplantation
| NCT ID | NCT06075563 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hong Kong Children's Hospital |
| Condition | Hematopoietic Organs; Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 23 participants |
| Start Date | 2023-05-29 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 23 participants in total. It began in 2023-05-29 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this comparative study, the investigators aim to compare prospective pediatric patients who receive total lymphoid irradiation (TLI) using tomotherapy with age- and disease-matched controls who receive conventional total body irradiation (TBI) as part of conditioning for haploidentical hematopoietic stem cell transplantation (HSCT) for both malignant and non-malignant diseases. The investigators shall evaluate graft failure-free, graft-versus-host disease (GVHD)-free survival, overall survival, frequency of rejection, GVHD, relapse of malignancy, adverse effects and post-transplant immunoreconstitution.
Eligibility Criteria
Inclusion Criteria: * Aged 0-18 years who requires allogeneic HSCT, has no human leukocyte antigen (HLA)-matched sibling donor but has an HLA-haploidentical donor. * Adequate organ function to tolerate the conditioning chemotherapy and radiotherapy * Karnofsky or Lansky performance status score ≥50 Exclusion Criteria: * Pregnant or lactating woman * HIV infection * Patients for whom alternative treatment is deemed more appropriate by treating physician * Patients who are unlikely to benefit from haploidentical hematopoietic stem cell transplantation, e.g., terminal malignancy with multiorgan failure
Contact & Investigator
Daniel Cheuk
PRINCIPAL INVESTIGATOR
Hong Kong Children's Hospital
Frequently Asked Questions
Who can join the NCT06075563 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Hematopoietic Organs; Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06075563 currently recruiting?
Yes, NCT06075563 is actively recruiting participants. Contact the research team at cheukkld@gmail.com for enrollment information.
Where is the NCT06075563 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT06075563 clinical trial?
NCT06075563 is sponsored by Hong Kong Children's Hospital. The principal investigator is Daniel Cheuk at Hong Kong Children's Hospital. The trial plans to enroll 23 participants.